Floatz logo

Flavopiridol

Recurrent Extragonadal Seminoma

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Extragonadal Seminoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Palbociclib
Abramson Cancer Center at Penn Medicine
Phase 2B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
Palifosfamide-Tris
Indiana University
Phase 2NR

Same molecule, other indications

Flavopiridol is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
Refractory Chronic Lymphocytic LeukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →